- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…BioSpace · 6d ago↗ source
- J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B dealJohnson & Johnson and AbbVie, the two pharma giants already in the psychedelic space, also eyed AtaiBeckley, according to a source familiar with the situation, but didn’t make an offer before E…Endpoints · 6d ago↗ source
- ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong KongAxiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX), followed by a co-listing on the Nasdaq—a strategy the company claims is the first U.S. biotech to use.